Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

CONMED's 2026 EPS consensus increased 3.7% over 60 days to $4.54, supported by BioBrace adoption, expanded AirSeal compatibility across Intuitive Surgical's X, Xi and da Vinci 5 platforms, and easing supply constraints. However, management expects approximately $0.35 per share of tariff-related headwinds in 2026, while Q2's reported 250bp adjusted operating-margin expansion was effectively flat excluding a nonrecurring $0.21-per-share tariff refund. Q3 2026 consensus calls for revenue of $336.8 million (-0.3% year over year) and EPS of $1.00 (-7.4%), reflecting near-term AirSeal growth deceleration and higher operating expenses.

Analysis

CNMD’s setup is less about a broad medtech rerating than proving that its robotic and orthopedic consumables can offset a structurally weaker margin bridge. The key underwriting question is whether disposable pull-through per installed AirSeal system and repeat BioBrace utilization accelerate enough to create operating leverage; without that, incremental commercial/R&D spending and tariff absorption leave consensus EPS vulnerable despite constructive revisions. The next earnings print is therefore a quality-of-growth event: procedure-linked consumables growth and gross-margin progression matter more than another headline EPS beat.

ISRG gains modestly from a more complete ecosystem around its installed base, but AirSeal compatibility does not materially alter ISRG’s economics or competitive moat. CNMD’s improved availability may instead pressure smaller orthopedic soft-tissue suppliers where surgeon switching is easier, while GMED remains the cleaner large-cap orthopedic execution vehicle with less dependence on a single accessory-platform adoption curve. Over 6-18 months, ASC migration is favorable to lower-cost, repeat-use surgical adjuncts, but purchasing committees may demand demonstrable procedure-time or complication benefits before broad standardization.

The contrarian view is that the market may capitalize temporary operational normalization as sustainable margin expansion. A tariff burden of roughly $0.35/share is meaningful against current earnings power, and prior-quarter margin optics were flattered by a nonrecurring item. Falsification of the cautious view would be two consecutive quarters of accelerating AirSeal disposable revenue, organic sales growth above the low-single-digit trajectory implied by near-term expectations, and underlying operating-margin expansion excluding tariff items.

Key Decisions for Investors

• Maintain CNMD as a watch-list long rather than add ahead of the next quarterly print. Upgrade only if management quantifies accelerating AirSeal disposable utilization and reaffirms or raises full-year underlying margin guidance; target a 10-15% upside on a credible reacceleration, with a 7-10% downside risk if revenue remains below plan and tariff mitigation is deferred.
• Pair trade for a 3-6 month horizon: long GMED / short CNMD in equal dollar amounts. GMED offers more diversified orthopedic growth and execution visibility, while CNMD bears concentrated AirSeal adoption and tariff-risk exposure; cover if CNMD reports two quarters of organic growth acceleration and ex-tariff margin expansion.
• Use ISRG as the cleaner robotic-surgery exposure rather than extrapolating CNMD’s accessory compatibility into a platform-level earnings catalyst. Do not treat CNMD’s expanded access as material to ISRG revenue or valuation absent evidence of incremental da Vinci procedure adoption.
• Set an earnings alert on CNMD: reduce or avoid exposure if third-quarter revenue misses the roughly $337M consensus level or if management cuts second-half AirSeal expectations; these outcomes would likely force 2026 EPS revisions lower despite recent estimate momentum.